Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Electronic Health Records | 50 | 2023 | 770 | 6.460 |
Why?
|
Natural Language Processing | 24 | 2023 | 76 | 5.700 |
Why?
|
Confidentiality | 5 | 2022 | 34 | 2.100 |
Why?
|
Genome-Wide Association Study | 21 | 2021 | 267 | 1.690 |
Why?
|
Data Anonymization | 2 | 2020 | 2 | 1.510 |
Why?
|
Algorithms | 18 | 2023 | 249 | 1.430 |
Why?
|
Computer Security | 5 | 2020 | 14 | 1.420 |
Why?
|
Humans | 98 | 2023 | 17807 | 1.390 |
Why?
|
Phenotype | 26 | 2023 | 169 | 1.350 |
Why?
|
Genetic Predisposition to Disease | 15 | 2019 | 420 | 1.270 |
Why?
|
Data Mining | 8 | 2017 | 27 | 1.200 |
Why?
|
Genetic Variation | 11 | 2016 | 98 | 1.140 |
Why?
|
Anaphylaxis | 2 | 2023 | 17 | 1.120 |
Why?
|
Alzheimer Disease | 8 | 2022 | 51 | 1.120 |
Why?
|
Polymorphism, Single Nucleotide | 16 | 2021 | 430 | 1.080 |
Why?
|
Medical Marijuana | 2 | 2022 | 26 | 1.030 |
Why?
|
Machine Learning | 3 | 2023 | 45 | 0.980 |
Why?
|
Analgesics, Opioid | 4 | 2020 | 237 | 0.950 |
Why?
|
Medical Records Systems, Computerized | 7 | 2017 | 99 | 0.940 |
Why?
|
Colonoscopy | 5 | 2018 | 263 | 0.940 |
Why?
|
Information Dissemination | 4 | 2017 | 59 | 0.860 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2014 | 248 | 0.820 |
Why?
|
Opioid-Related Disorders | 4 | 2019 | 164 | 0.810 |
Why?
|
Psychotic Disorders | 2 | 2018 | 46 | 0.770 |
Why?
|
Personally Identifiable Information | 1 | 2019 | 1 | 0.740 |
Why?
|
Female | 55 | 2022 | 12662 | 0.710 |
Why?
|
Adult | 39 | 2022 | 7576 | 0.640 |
Why?
|
Early Detection of Cancer | 3 | 2018 | 493 | 0.640 |
Why?
|
Patient Care Planning | 1 | 2018 | 52 | 0.630 |
Why?
|
Male | 46 | 2022 | 10035 | 0.630 |
Why?
|
Middle Aged | 45 | 2022 | 7997 | 0.620 |
Why?
|
Genomics | 10 | 2023 | 72 | 0.600 |
Why?
|
Aged | 36 | 2022 | 6191 | 0.590 |
Why?
|
Patient Identification Systems | 1 | 2016 | 5 | 0.590 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 264 | 0.580 |
Why?
|
Mental Health Services | 1 | 2018 | 158 | 0.550 |
Why?
|
Inappropriate Prescribing | 1 | 2015 | 10 | 0.550 |
Why?
|
Breast Neoplasms | 2 | 2014 | 1005 | 0.550 |
Why?
|
Narcotic Antagonists | 1 | 2015 | 17 | 0.540 |
Why?
|
Pain | 1 | 2015 | 82 | 0.530 |
Why?
|
Biomarkers | 5 | 2019 | 303 | 0.530 |
Why?
|
Patient Satisfaction | 4 | 2015 | 236 | 0.520 |
Why?
|
Internet | 6 | 2013 | 252 | 0.510 |
Why?
|
Adolescent | 18 | 2022 | 3642 | 0.460 |
Why?
|
United States | 21 | 2022 | 4046 | 0.450 |
Why?
|
Washington | 7 | 2021 | 383 | 0.440 |
Why?
|
Case-Control Studies | 11 | 2020 | 1169 | 0.430 |
Why?
|
Adenoma | 3 | 2018 | 100 | 0.420 |
Why?
|
Spouse Abuse | 5 | 2009 | 14 | 0.410 |
Why?
|
Pattern Recognition, Automated | 3 | 2015 | 5 | 0.400 |
Why?
|
Cholesterol, LDL | 4 | 2019 | 126 | 0.390 |
Why?
|
Health Status | 3 | 2009 | 330 | 0.380 |
Why?
|
Primary Health Care | 4 | 2022 | 829 | 0.360 |
Why?
|
Colorectal Neoplasms | 4 | 2019 | 630 | 0.360 |
Why?
|
Electronic Mail | 3 | 2009 | 58 | 0.350 |
Why?
|
Mendelian Randomization Analysis | 2 | 2020 | 23 | 0.340 |
Why?
|
Proprotein Convertase 9 | 2 | 2019 | 4 | 0.330 |
Why?
|
Risk Factors | 15 | 2020 | 3390 | 0.330 |
Why?
|
Data Collection | 5 | 2019 | 281 | 0.330 |
Why?
|
Radiology Information Systems | 1 | 2007 | 1 | 0.320 |
Why?
|
Forms and Records Control | 1 | 2007 | 8 | 0.320 |
Why?
|
European Continental Ancestry Group | 5 | 2018 | 565 | 0.320 |
Why?
|
Prevalence | 10 | 2021 | 891 | 0.320 |
Why?
|
Receptors, Immunologic | 3 | 2017 | 4 | 0.320 |
Why?
|
Membrane Glycoproteins | 3 | 2017 | 5 | 0.310 |
Why?
|
tau Proteins | 3 | 2017 | 6 | 0.310 |
Why?
|
Databases, Genetic | 3 | 2016 | 13 | 0.310 |
Why?
|
Hypertension | 4 | 2017 | 493 | 0.310 |
Why?
|
Domestic Violence | 4 | 2007 | 13 | 0.300 |
Why?
|
Aortic Aneurysm, Abdominal | 2 | 2016 | 9 | 0.300 |
Why?
|
International Classification of Diseases | 6 | 2022 | 93 | 0.300 |
Why?
|
Physicians | 2 | 2018 | 141 | 0.290 |
Why?
|
Vocabulary, Controlled | 4 | 2015 | 5 | 0.280 |
Why?
|
Young Adult | 11 | 2018 | 2439 | 0.280 |
Why?
|
Patient Access to Records | 1 | 2006 | 19 | 0.280 |
Why?
|
Genotype | 8 | 2018 | 267 | 0.270 |
Why?
|
Herpes Zoster | 2 | 2018 | 87 | 0.270 |
Why?
|
Quality Indicators, Health Care | 2 | 2018 | 199 | 0.270 |
Why?
|
Language | 2 | 2023 | 50 | 0.260 |
Why?
|
Documentation | 2 | 2022 | 47 | 0.260 |
Why?
|
Antihypertensive Agents | 3 | 2017 | 171 | 0.260 |
Why?
|
Age Factors | 7 | 2015 | 950 | 0.260 |
Why?
|
Genetic Loci | 4 | 2017 | 64 | 0.250 |
Why?
|
Amyloid beta-Peptides | 4 | 2017 | 8 | 0.250 |
Why?
|
Aged, 80 and over | 11 | 2019 | 1941 | 0.250 |
Why?
|
African Americans | 3 | 2017 | 485 | 0.240 |
Why?
|
Retrospective Studies | 12 | 2020 | 2462 | 0.240 |
Why?
|
Cataract | 2 | 2015 | 9 | 0.240 |
Why?
|
Knowledge Bases | 3 | 2022 | 6 | 0.230 |
Why?
|
Databases, Factual | 3 | 2021 | 331 | 0.230 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2022 | 546 | 0.230 |
Why?
|
Neoplasms | 1 | 2007 | 449 | 0.220 |
Why?
|
Medical Informatics | 2 | 2019 | 45 | 0.220 |
Why?
|
Health Care Surveys | 2 | 2022 | 253 | 0.220 |
Why?
|
Women's Health | 3 | 2009 | 211 | 0.220 |
Why?
|
Follow-Up Studies | 5 | 2018 | 1249 | 0.220 |
Why?
|
Hypothyroidism | 2 | 2011 | 10 | 0.210 |
Why?
|
Pancreatitis | 1 | 2022 | 49 | 0.210 |
Why?
|
Delivery of Health Care | 3 | 2019 | 446 | 0.210 |
Why?
|
Spinal Stenosis | 1 | 2021 | 5 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2019 | 733 | 0.210 |
Why?
|
Patient Reported Outcome Measures | 1 | 2022 | 58 | 0.210 |
Why?
|
Membrane Proteins | 3 | 2019 | 44 | 0.210 |
Why?
|
Cognitive Dysfunction | 1 | 2022 | 43 | 0.200 |
Why?
|
Genetic Pleiotropy | 1 | 2021 | 10 | 0.200 |
Why?
|
Low Back Pain | 1 | 2021 | 54 | 0.200 |
Why?
|
Cohort Studies | 11 | 2017 | 2606 | 0.200 |
Why?
|
Self Report | 1 | 2022 | 244 | 0.190 |
Why?
|
Predictive Value of Tests | 5 | 2022 | 354 | 0.190 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 3 | 2013 | 50 | 0.190 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2019 | 1 | 0.190 |
Why?
|
Narration | 2 | 2023 | 13 | 0.190 |
Why?
|
Anticholesteremic Agents | 1 | 2019 | 15 | 0.180 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 338 | 0.180 |
Why?
|
Risk | 6 | 2019 | 558 | 0.180 |
Why?
|
Non-alcoholic Fatty Liver Disease | 1 | 2019 | 7 | 0.180 |
Why?
|
Odds Ratio | 6 | 2018 | 695 | 0.180 |
Why?
|
Colonic Polyps | 1 | 2019 | 36 | 0.180 |
Why?
|
Pharmacogenetics | 2 | 2016 | 17 | 0.180 |
Why?
|
Ambulatory Care Facilities | 1 | 2019 | 82 | 0.170 |
Why?
|
Postoperative Complications | 1 | 2020 | 100 | 0.170 |
Why?
|
Proteome | 1 | 2018 | 3 | 0.170 |
Why?
|
Carotid Artery Diseases | 1 | 2018 | 12 | 0.170 |
Why?
|
Dyslipidemias | 1 | 2019 | 63 | 0.170 |
Why?
|
Personality | 1 | 2018 | 10 | 0.170 |
Why?
|
Computational Biology | 2 | 2015 | 30 | 0.170 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 70 | 0.170 |
Why?
|
Depressive Disorder | 2 | 2014 | 234 | 0.170 |
Why?
|
Biomedical Research | 3 | 2017 | 90 | 0.170 |
Why?
|
Pilot Projects | 3 | 2015 | 233 | 0.170 |
Why?
|
Drug Overdose | 1 | 2019 | 58 | 0.160 |
Why?
|
Risk Assessment | 4 | 2019 | 1122 | 0.160 |
Why?
|
Abdominal Pain | 2 | 2015 | 17 | 0.160 |
Why?
|
Utilization Review | 1 | 2018 | 55 | 0.160 |
Why?
|
Reproducibility of Results | 3 | 2015 | 391 | 0.160 |
Why?
|
Battered Women | 2 | 2009 | 3 | 0.160 |
Why?
|
Chromosomes, Human | 2 | 2018 | 5 | 0.160 |
Why?
|
Pathology, Clinical | 1 | 2017 | 15 | 0.160 |
Why?
|
Immunity, Innate | 1 | 2017 | 1 | 0.160 |
Why?
|
Microglia | 1 | 2017 | 1 | 0.160 |
Why?
|
Phospholipase C gamma | 1 | 2017 | 1 | 0.160 |
Why?
|
Patient Admission | 1 | 2018 | 73 | 0.160 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2017 | 16 | 0.160 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 155 | 0.160 |
Why?
|
Prostaglandin-E Synthases | 1 | 2017 | 1 | 0.150 |
Why?
|
Public Opinion | 1 | 2017 | 7 | 0.150 |
Why?
|
Drug Resistance | 1 | 2017 | 31 | 0.150 |
Why?
|
Informed Consent | 1 | 2017 | 22 | 0.150 |
Why?
|
Telemedicine | 2 | 2013 | 191 | 0.150 |
Why?
|
Epistasis, Genetic | 1 | 2016 | 4 | 0.150 |
Why?
|
Chitinase-3-Like Protein 1 | 1 | 2016 | 2 | 0.150 |
Why?
|
Affective Disorders, Psychotic | 1 | 2017 | 11 | 0.150 |
Why?
|
Biological Specimen Banks | 1 | 2017 | 13 | 0.150 |
Why?
|
Clinical Competence | 1 | 2017 | 106 | 0.150 |
Why?
|
Intracranial Aneurysm | 1 | 2016 | 4 | 0.150 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2016 | 3 | 0.150 |
Why?
|
Schizophrenia | 1 | 2017 | 78 | 0.140 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 82 | 0.140 |
Why?
|
Triglycerides | 1 | 2016 | 86 | 0.140 |
Why?
|
Neanderthals | 1 | 2016 | 1 | 0.140 |
Why?
|
Quality Improvement | 2 | 2015 | 209 | 0.140 |
Why?
|
Disease | 1 | 2016 | 6 | 0.140 |
Why?
|
Software | 4 | 2019 | 25 | 0.140 |
Why?
|
Ether-A-Go-Go Potassium Channels | 1 | 2016 | 2 | 0.140 |
Why?
|
NAV1.5 Voltage-Gated Sodium Channel | 1 | 2016 | 2 | 0.140 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2015 | 10 | 0.140 |
Why?
|
Laboratories | 1 | 2016 | 24 | 0.140 |
Why?
|
Arrhythmias, Cardiac | 1 | 2016 | 29 | 0.140 |
Why?
|
Morbidity | 2 | 2019 | 64 | 0.140 |
Why?
|
Hemochromatosis | 1 | 2015 | 10 | 0.140 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2015 | 9 | 0.140 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2015 | 8 | 0.140 |
Why?
|
Kv Channel-Interacting Proteins | 1 | 2015 | 2 | 0.140 |
Why?
|
Back Pain | 1 | 2015 | 38 | 0.140 |
Why?
|
Health Care Costs | 2 | 2008 | 246 | 0.140 |
Why?
|
Patient Outcome Assessment | 1 | 2015 | 29 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2018 | 272 | 0.140 |
Why?
|
Cough | 1 | 2015 | 18 | 0.140 |
Why?
|
Models, Genetic | 1 | 2015 | 27 | 0.140 |
Why?
|
Physician-Patient Relations | 2 | 2009 | 200 | 0.130 |
Why?
|
Gene-Environment Interaction | 1 | 2015 | 22 | 0.130 |
Why?
|
Ventricular Function, Left | 1 | 2015 | 48 | 0.130 |
Why?
|
RNA, Untranslated | 1 | 2014 | 1 | 0.130 |
Why?
|
Data Interpretation, Statistical | 1 | 2015 | 77 | 0.130 |
Why?
|
Thyrotropin | 1 | 2014 | 8 | 0.130 |
Why?
|
Sensitivity and Specificity | 4 | 2019 | 316 | 0.130 |
Why?
|
Artificial Intelligence | 1 | 2014 | 14 | 0.130 |
Why?
|
Sarcoma, Kaposi | 2 | 2006 | 15 | 0.130 |
Why?
|
Stroke Volume | 1 | 2015 | 95 | 0.130 |
Why?
|
Biological Ontologies | 1 | 2014 | 1 | 0.130 |
Why?
|
Writing | 1 | 2014 | 13 | 0.130 |
Why?
|
Open Reading Frames | 1 | 2014 | 1 | 0.130 |
Why?
|
Child | 8 | 2017 | 2453 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 94 | 0.130 |
Why?
|
Quality of Life | 2 | 2009 | 498 | 0.130 |
Why?
|
Herpesvirus 3, Human | 1 | 2014 | 47 | 0.130 |
Why?
|
Drug Prescriptions | 1 | 2015 | 157 | 0.120 |
Why?
|
Reference Standards | 1 | 2014 | 18 | 0.120 |
Why?
|
Phospholipase D | 1 | 2013 | 1 | 0.120 |
Why?
|
Asthma | 1 | 2017 | 303 | 0.120 |
Why?
|
Neoplasm Grading | 1 | 2014 | 48 | 0.120 |
Why?
|
Medical Informatics Applications | 1 | 2013 | 10 | 0.120 |
Why?
|
Medical Record Linkage | 1 | 2013 | 44 | 0.120 |
Why?
|
Mammography | 1 | 2015 | 169 | 0.120 |
Why?
|
Research Design | 2 | 2019 | 390 | 0.120 |
Why?
|
Body Mass Index | 4 | 2020 | 951 | 0.120 |
Why?
|
Pharmacoepidemiology | 1 | 2013 | 23 | 0.120 |
Why?
|
Leukocyte Count | 1 | 2013 | 23 | 0.120 |
Why?
|
Obesity | 1 | 2020 | 831 | 0.110 |
Why?
|
Sexual Partners | 3 | 2009 | 40 | 0.110 |
Why?
|
Linkage Disequilibrium | 3 | 2017 | 42 | 0.110 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 1275 | 0.110 |
Why?
|
Linear Models | 4 | 2016 | 243 | 0.110 |
Why?
|
Disease Progression | 3 | 2019 | 259 | 0.110 |
Why?
|
Pneumonia | 1 | 2013 | 55 | 0.110 |
Why?
|
Rhabdomyolysis | 1 | 2012 | 2 | 0.110 |
Why?
|
Genome, Human | 3 | 2017 | 46 | 0.110 |
Why?
|
Radiography | 2 | 2013 | 41 | 0.110 |
Why?
|
Gene Frequency | 3 | 2017 | 52 | 0.110 |
Why?
|
Information Storage and Retrieval | 1 | 2012 | 17 | 0.110 |
Why?
|
Atherosclerosis | 1 | 2013 | 51 | 0.110 |
Why?
|
Hashimoto Disease | 1 | 2011 | 1 | 0.110 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 7 | 0.110 |
Why?
|
Lipase | 2 | 2022 | 3 | 0.100 |
Why?
|
Communication | 2 | 2021 | 201 | 0.100 |
Why?
|
Mass Screening | 2 | 2022 | 661 | 0.100 |
Why?
|
Cardiovascular Diseases | 1 | 2016 | 605 | 0.100 |
Why?
|
Patient Compliance | 2 | 2010 | 306 | 0.100 |
Why?
|
Incidence | 4 | 2018 | 1289 | 0.100 |
Why?
|
Heart Failure | 1 | 2015 | 385 | 0.090 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 177 | 0.090 |
Why?
|
Logistic Models | 3 | 2020 | 949 | 0.090 |
Why?
|
Privacy | 2 | 2021 | 9 | 0.090 |
Why?
|
Patient Selection | 1 | 2010 | 191 | 0.090 |
Why?
|
Evaluation Studies as Topic | 1 | 2008 | 34 | 0.090 |
Why?
|
Crime Victims | 1 | 2009 | 26 | 0.080 |
Why?
|
Remote Consultation | 1 | 2008 | 12 | 0.080 |
Why?
|
Men's Health | 1 | 2008 | 21 | 0.080 |
Why?
|
Datasets as Topic | 2 | 2019 | 18 | 0.080 |
Why?
|
Patient Care | 1 | 2008 | 38 | 0.080 |
Why?
|
Pharmaceutical Services | 1 | 2008 | 35 | 0.080 |
Why?
|
Abstracting and Indexing as Topic | 1 | 2007 | 1 | 0.080 |
Why?
|
Attitude to Computers | 1 | 2007 | 17 | 0.080 |
Why?
|
Signal Transduction | 2 | 2019 | 33 | 0.080 |
Why?
|
Haplotypes | 2 | 2018 | 45 | 0.080 |
Why?
|
Sex Factors | 2 | 2009 | 633 | 0.080 |
Why?
|
Homozygote | 2 | 2018 | 16 | 0.080 |
Why?
|
Child Abuse | 1 | 2008 | 43 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2015 | 592 | 0.080 |
Why?
|
Ovarian Neoplasms | 1 | 2007 | 48 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 188 | 0.080 |
Why?
|
Mental Health | 1 | 2008 | 158 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 324 | 0.070 |
Why?
|
Mothers | 1 | 2007 | 109 | 0.070 |
Why?
|
Saliva | 1 | 2006 | 14 | 0.070 |
Why?
|
Child Health Services | 1 | 2007 | 126 | 0.070 |
Why?
|
Genotyping Techniques | 2 | 2016 | 28 | 0.070 |
Why?
|
HIV Seropositivity | 1 | 2006 | 32 | 0.070 |
Why?
|
Amino Acid Sequence | 2 | 2017 | 11 | 0.070 |
Why?
|
Homosexuality, Male | 1 | 2006 | 39 | 0.070 |
Why?
|
Health Expenditures | 1 | 2007 | 78 | 0.070 |
Why?
|
Exome | 2 | 2017 | 27 | 0.070 |
Why?
|
Heterozygote | 2 | 2016 | 31 | 0.070 |
Why?
|
Alleles | 2 | 2016 | 95 | 0.070 |
Why?
|
Health Services | 1 | 2007 | 110 | 0.070 |
Why?
|
Diffusion of Innovation | 1 | 2006 | 44 | 0.070 |
Why?
|
Socioeconomic Factors | 3 | 2017 | 663 | 0.070 |
Why?
|
Apolipoproteins E | 2 | 2017 | 13 | 0.070 |
Why?
|
Precision Medicine | 2 | 2016 | 32 | 0.070 |
Why?
|
Group Practice | 1 | 2005 | 26 | 0.070 |
Why?
|
ROC Curve | 2 | 2015 | 82 | 0.060 |
Why?
|
Genetic Markers | 2 | 2016 | 32 | 0.060 |
Why?
|
Surveys and Questionnaires | 2 | 2006 | 1330 | 0.060 |
Why?
|
Child, Preschool | 3 | 2017 | 1404 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2016 | 22 | 0.060 |
Why?
|
Europe | 2 | 2014 | 39 | 0.060 |
Why?
|
Genetic Association Studies | 2 | 2014 | 37 | 0.060 |
Why?
|
Age of Onset | 2 | 2014 | 85 | 0.060 |
Why?
|
Brain | 2 | 2014 | 47 | 0.060 |
Why?
|
Peptide Fragments | 2 | 2013 | 30 | 0.060 |
Why?
|
Prospective Studies | 2 | 2018 | 1270 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 59 | 0.060 |
Why?
|
Herpesvirus 8, Human | 1 | 2002 | 1 | 0.060 |
Why?
|
Herpesviridae Infections | 1 | 2002 | 3 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2002 | 55 | 0.050 |
Why?
|
Acyclovir | 1 | 2002 | 6 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2002 | 5 | 0.050 |
Why?
|
Herpes Genitalis | 1 | 2002 | 5 | 0.050 |
Why?
|
Registries | 2 | 2017 | 483 | 0.050 |
Why?
|
Acute Disease | 1 | 2022 | 134 | 0.050 |
Why?
|
Colorado | 2 | 2017 | 206 | 0.050 |
Why?
|
Lumbar Vertebrae | 1 | 2021 | 21 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2002 | 85 | 0.050 |
Why?
|
Models, Biological | 1 | 2021 | 33 | 0.050 |
Why?
|
Down-Regulation | 1 | 2019 | 14 | 0.050 |
Why?
|
National Human Genome Research Institute (U.S.) | 1 | 2019 | 2 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2019 | 38 | 0.050 |
Why?
|
Heroin | 1 | 2019 | 6 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2019 | 1243 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2019 | 48 | 0.040 |
Why?
|
Community Networks | 1 | 2019 | 28 | 0.040 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 1 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2018 | 1 | 0.040 |
Why?
|
Proteomics | 1 | 2018 | 8 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2018 | 24 | 0.040 |
Why?
|
Self-Injurious Behavior | 1 | 2019 | 39 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2018 | 63 | 0.040 |
Why?
|
Pharmacists | 2 | 2008 | 44 | 0.040 |
Why?
|
African Continental Ancestry Group | 1 | 2018 | 167 | 0.040 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2017 | 1 | 0.040 |
Why?
|
Protein Interaction Maps | 1 | 2017 | 1 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 2 | 2008 | 15 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2019 | 248 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 36 | 0.040 |
Why?
|
Endophenotypes | 1 | 2017 | 1 | 0.040 |
Why?
|
Airway Remodeling | 1 | 2017 | 1 | 0.040 |
Why?
|
Computer Communication Networks | 1 | 2017 | 19 | 0.040 |
Why?
|
Multifactor Dimensionality Reduction | 1 | 2016 | 1 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2017 | 36 | 0.040 |
Why?
|
Northwestern United States | 1 | 2017 | 46 | 0.040 |
Why?
|
Stroke | 1 | 2019 | 301 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2016 | 3 | 0.040 |
Why?
|
ERG1 Potassium Channel | 1 | 2016 | 2 | 0.040 |
Why?
|
Brugada Syndrome | 1 | 2016 | 2 | 0.040 |
Why?
|
Keratosis, Actinic | 1 | 2016 | 6 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 46 | 0.040 |
Why?
|
Random Allocation | 1 | 2016 | 43 | 0.040 |
Why?
|
Incidental Findings | 1 | 2016 | 30 | 0.040 |
Why?
|
Illinois | 1 | 2015 | 10 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 57 | 0.030 |
Why?
|
Penetrance | 1 | 2015 | 5 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2015 | 9 | 0.030 |
Why?
|
Hemochromatosis Protein | 1 | 2015 | 9 | 0.030 |
Why?
|
Scotland | 1 | 2015 | 3 | 0.030 |
Why?
|
Access to Information | 1 | 2015 | 15 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2015 | 1 | 0.030 |
Why?
|
Animals | 1 | 2016 | 233 | 0.030 |
Why?
|
Population Groups | 1 | 2015 | 8 | 0.030 |
Why?
|
Genetic Testing | 1 | 2016 | 86 | 0.030 |
Why?
|
Blood Pressure | 1 | 2017 | 282 | 0.030 |
Why?
|
Area Under Curve | 1 | 2015 | 34 | 0.030 |
Why?
|
Africa | 1 | 2014 | 6 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2014 | 3 | 0.030 |
Why?
|
Semantics | 1 | 2014 | 1 | 0.030 |
Why?
|
Textbooks as Topic | 1 | 2014 | 1 | 0.030 |
Why?
|
Clinical Medicine | 1 | 2014 | 6 | 0.030 |
Why?
|
RNA, Long Noncoding | 1 | 2014 | 6 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2007 | 691 | 0.030 |
Why?
|
Data Curation | 1 | 2014 | 2 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2014 | 1 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2014 | 1 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 19 | 0.030 |
Why?
|
Blood Glucose | 1 | 2016 | 342 | 0.030 |
Why?
|
Drug Therapy | 1 | 2014 | 25 | 0.030 |
Why?
|
Models, Psychological | 1 | 2014 | 26 | 0.030 |
Why?
|
Program Evaluation | 1 | 2015 | 235 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 39 | 0.030 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2013 | 2 | 0.030 |
Why?
|
Proteolysis | 1 | 2013 | 2 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 3 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 96 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2013 | 26 | 0.030 |
Why?
|
Prognosis | 1 | 2015 | 617 | 0.030 |
Why?
|
Serine | 1 | 2013 | 1 | 0.030 |
Why?
|
Phosphorylation | 1 | 2013 | 5 | 0.030 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2013 | 5 | 0.030 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2013 | 5 | 0.030 |
Why?
|
Muscle Proteins | 1 | 2013 | 6 | 0.030 |
Why?
|
Transcription Factors | 1 | 2013 | 19 | 0.030 |
Why?
|
Receptors, Chemokine | 1 | 2013 | 1 | 0.030 |
Why?
|
Receptors, Lysophosphatidic Acid | 1 | 2013 | 1 | 0.030 |
Why?
|
GATA2 Transcription Factor | 1 | 2013 | 1 | 0.030 |
Why?
|
Interferon Regulatory Factors | 1 | 2013 | 4 | 0.030 |
Why?
|
Integrin alpha4 | 1 | 2013 | 3 | 0.030 |
Why?
|
Monocytes | 1 | 2013 | 6 | 0.030 |
Why?
|
Ethnic Groups | 1 | 2017 | 503 | 0.030 |
Why?
|
Chronic Pain | 1 | 2015 | 125 | 0.030 |
Why?
|
Muscular Diseases | 1 | 2012 | 2 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2014 | 454 | 0.030 |
Why?
|
Pharmacies | 1 | 2012 | 11 | 0.030 |
Why?
|
Simvastatin | 1 | 2012 | 11 | 0.030 |
Why?
|
Genome | 1 | 2011 | 6 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 129 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2012 | 106 | 0.030 |
Why?
|
Depression | 1 | 2016 | 501 | 0.020 |
Why?
|
Nursing Care | 1 | 2010 | 4 | 0.020 |
Why?
|
Nursing Staff, Hospital | 1 | 2010 | 13 | 0.020 |
Why?
|
Sample Size | 1 | 2010 | 32 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 46 | 0.020 |
Why?
|
Peripheral Arterial Disease | 1 | 2010 | 13 | 0.020 |
Why?
|
Allied Health Personnel | 1 | 2010 | 14 | 0.020 |
Why?
|
California | 1 | 2017 | 2275 | 0.020 |
Why?
|
Sigmoidoscopy | 1 | 2010 | 67 | 0.020 |
Why?
|
Genital Diseases, Female | 1 | 2009 | 10 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2009 | 29 | 0.020 |
Why?
|
Reminder Systems | 1 | 2010 | 84 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2009 | 21 | 0.020 |
Why?
|
Telephone | 1 | 2010 | 169 | 0.020 |
Why?
|
Infant | 1 | 2013 | 1194 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2009 | 54 | 0.020 |
Why?
|
Occult Blood | 1 | 2010 | 154 | 0.020 |
Why?
|
Health Care Reform | 1 | 2008 | 34 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2008 | 47 | 0.020 |
Why?
|
Models, Organizational | 1 | 2008 | 69 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 313 | 0.020 |
Why?
|
Child Abuse, Sexual | 1 | 2008 | 15 | 0.020 |
Why?
|
Probability | 1 | 2008 | 87 | 0.020 |
Why?
|
Systems Integration | 1 | 2007 | 5 | 0.020 |
Why?
|
Online Systems | 1 | 2007 | 9 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 161 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 162 | 0.020 |
Why?
|
Process Assessment (Health Care) | 1 | 2007 | 28 | 0.020 |
Why?
|
Disease Management | 1 | 2008 | 144 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2007 | 116 | 0.020 |
Why?
|
Social Alienation | 1 | 2006 | 1 | 0.020 |
Why?
|
Oropharynx | 1 | 2006 | 2 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2006 | 10 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2008 | 216 | 0.020 |
Why?
|
Mental Disorders | 1 | 2009 | 279 | 0.020 |
Why?
|
Child Care | 1 | 2006 | 13 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2007 | 321 | 0.020 |
Why?
|
Income | 1 | 2006 | 95 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2008 | 228 | 0.020 |
Why?
|
Chronic Disease | 1 | 2009 | 460 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2008 | 315 | 0.020 |
Why?
|
Insurance, Health | 1 | 2007 | 222 | 0.020 |
Why?
|
Time Factors | 1 | 2008 | 1108 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2002 | 21 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2002 | 53 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2002 | 161 | 0.010 |
Why?
|